Effect of PGE₂ biosynthesis inhibition on DC progenitor proliferation and survival. (A) CFDA dilution 3 days after in vitro culture of CDPs that had undergone FACS in Flt3L-supplemented medium with or without indomethacin (mean ± SEM; n = 4 mice). (B) Representative dot plots of BrdU incorporation in CDPs of BrdU-treated mice after indomethacin treatment. (Left) Average frequency of BrdU⁺ CDPs; (right) total CDPs per femur (mean ± SEM, 2 experiments; n = 3 mice/group/experiment). (C) CDP-enriched Lin^neg BM cells were cultured for 5 days in Flt3L-supplemented medium with or without indomethacin, and annexin V (left) and active caspase-3 (right) expressions were determined in pre-cDC gated cell population (mean ± SEM; 2 experiments; n = 3 mice/experiment). (D) Active caspase-3 expression in BM CDPs and pre-cDCs, and CDP and pre-cDC viability (insets) in mice treated for 6 days with indomethacin (mean ± SEM from 5 mice per group assayed individually; expressed as percentage of control). *P < .05. V indicates vehicle; and Indo, indomethacin.